Association Study Of Polymorphisms In The Human Drug Metabolism Enzyme Gene And Bladder Cancer Risk

Background and ObjiectiveBladder cancer is the first common cancer in urology. Bladder cancer is considered a multifactorial disease where multiple exposures interact with the individual genetic background resulting in risk modulation. The genic polymorphism of drug metabolism enzyme was important key to susceptibility to bladder cancer. Many literiturs have reported that NAT2, GSTT1/GSTM1 and CYP (CYP1A2, CYP2D6 and CYP2C19) were associated with breast cancer, prostate cancer and tumors in neck, oral cavity and degesitive tract. However, there were conflict conclusions on study between bladder cancer, genic polymorphism and environmental factors. The aim of our study is to elucidate whether some polymorphisms of N-acetyltransferase 2 (NAT2), glutathione S-transferase (GST), and Cytochrome P450 2C19 (CYP 2C19) genes might be associated with the risk of bladder cancer. The potential interactions of these metabolic enzymes with the risk factors such as smoking tobacco, occupational exposure and well-done meat consumption were also explored.Materials and MethodsSujects The study population consisted of a series of bladder cancer patients and non-cancer controls admitted to the department of urology, the first affiliated hospital of Zhengzhou University, from March, 2004 to December, 2005. The study design was approved by the Committee on Human Research of Zhengzhou University. The study subjects gave informed consent prior to participation in the study. Patients who were diagnosed as incident bladder cancer cases with histopathological confirmation, and from whom a peripheral blood sample was drawn and selected as cases (n=108). Controls (n=112) who were individuals with no present or previous history of bladder cancer or other tumors, were simultaneously recruited in the same...